Halozyme Therapeutics, Inc.
HALO
$74.93
$1.532.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 65.22% | 52.25% | 57.71% | 54.57% | 44.32% |
| Total Depreciation and Amortization | -0.10% | -0.67% | -1.27% | 18.63% | 5.69% |
| Total Amortization of Deferred Charges | 0.90% | 0.92% | 0.63% | 0.36% | -22.23% |
| Total Other Non-Cash Items | -75.11% | -38.74% | -36.44% | 10.60% | -31.20% |
| Change in Net Operating Assets | -74.79% | -234.17% | -130.86% | -697.22% | 34.85% |
| Cash from Operations | 30.43% | 16.90% | 23.29% | 9.30% | 37.30% |
| Capital Expenditure | 39.30% | -8.56% | 30.06% | 31.92% | 10.98% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 33.32% | -134.32% | -208.80% | -240.25% | -4,165.65% |
| Cash from Investing | 33.64% | -126.47% | -171.10% | -232.54% | -2,632.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Common Stock | 46.26% | 254.30% | 254.30% | 125.09% | 32.46% |
| Repurchase of Common Stock | -118.95% | -0.21% | 37.91% | -67.26% | 28.01% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -123.85% | 9.09% | 46.36% | -46.55% | -40.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -278.38% | -82.73% | 97.83% | -194.74% | -125.67% |